CCIA
GSK icon

Campbell & Co Investment Adviser’s GSK GSK Stock Holding History

Campbell & Co Investment Adviser’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.4M Buy
83,989
+79,461
+1,755% +$4.2M 0.23% 103
2026
Q1 		$250K Sell
4,528
-50,456
-92% -$2.73M 0.01% 917
2025
Q4 		$2.7M Buy
54,984
+30,055
+121% +$1.4M 0.13% 244
2025
Q3 		$1.08M Sell
24,929
-896
-3% -$35K 0.08% 399
2025
Q2 		$992K Buy
25,825
+15,135
+142% +$578K 0.06% 499
2025
Q1 		$414K Buy
+10,690
New +$391K 0.03% 758
2024
Q4 		– Sell
-125,236
Closed -$5.12M – 1169
2024
Q3 		$5.12M Buy
125,236
+39,394
+46% +$1.61M 0.38% 35
2024
Q2 		$3.3M Buy
+85,842
New +$3.61M 0.28% 68
2024
Q1 		– Sell
-13,231
Closed -$490K – 1220
2023
Q4 		$490K Buy
+13,231
New +$475K 0.04% 721
2023
Q3 		– Sell
-25,272
Closed -$901K – 1039
2023
Q2 		$901K Sell
25,272
-4,568
-15% -$164K 0.16% 191
2023
Q1 		$1.06M Buy
+29,840
New +$1.04M 0.2% 137
2022
Q4 		– Sell
-193,518
Closed -$5.7M – 864
2022
Q3 		$5.7M Buy
+193,518
New +$7.33M 1.29% 1
2020
Q4 		– Sell
-8,282
Closed -$390K – 470
2020
Q3 		$390K Buy
+8,282
New +$415K 0.29% 119
2019
Q1 		– Sell
-4,270
Closed -$226K – 549
2018
Q4 		$226K Buy
+4,270
New +$210K 0.22% 258
2013
Q3 		– Sell
-30,117
Closed -$1.88M – 293
2013
Q2 		$1.88M Buy
+30,117
New +$1.91M 0.36% 85

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Campbell & Co Investment Adviser's GSK Position: Q2 2026 in Review

Campbell & Co Investment Adviser increased its GSK (GSK) stake by 1,755% in Q2 2026, buying an estimated $4.2M and bringing the position to 83,989 shares worth $4.4M. The position accounts for 0.23% of the portfolio, ranked #103.

Campbell & Co Investment Adviser first reported a position in GSK in Q2 2013 and has held it in 15 quarters since. The position peaked at $5.7M in Q3 2022. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Campbell & Co Investment Adviser held 83,989 shares of GSK worth $4.4M as of Q2 2026.
  • Campbell & Co Investment Adviser bought 79,461 GSK shares in Q2 2026, an estimated $4.2M.
  • GSK made up 0.23% of Campbell & Co Investment Adviser's portfolio in Q2 2026, its #103 holding.
  • Campbell & Co Investment Adviser first reported a position in GSK in Q2 2013 and has held it in 15 quarters since.
  • Campbell & Co Investment Adviser's GSK position peaked at $5.7M in Q3 2022.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.